Studies on the molecular pharmacology of antidepressants have lead to a reinterpretation of earlier models of the neuropathology of depression. Noradrenergic and serotonergic hypotheses of depression have been expanded to include postsynaptic intracellular signal transduction pathways and regulation of gene expression. Because much of this evidence was obtained from postmortem brain, there has been increased interest in the use of this tissue to study depression. In the following pages, we will review the postmortem brain studies in depressed individuals focusing on neurotransmitter systems, signal transduction, and structural abnormalities.
Kessler RC, McGonagle KA, Zhao S, Nelson CB, Hughes M, Eshleman S, et al.Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey. Arch Gen Psychiatry1994;51:8-19.
2.
Potter WZ, Manji HK, Rudorfer MV. Tricyclics and tetracyclics. In: Schatzberg AF, Nemeroff CB, editors. Textbook of psychopharmacology. Washington, DC: American Psychiatric Press; 1995. p. 141-160.
3.
Wells KB, Golding JM, Burnam MA. Psychiatric disorder and limitations in physical functioning in a sample of the Los Angeles general population. Am J Psychiatry1988;145:712-717.
4.
Kalpana IN, Musselman DL, Schatzberg AF, Nemeroff CB. Biology of mood disorders. In: Schatzberg AF, Nemeroff CB, editors. Textbook of psychopharmacology. Washington, DC: American Psychiatric Press; 1995. p. 439-478.
5.
Drevets WC. Prefrontal cortical-amygdalar metabolism in major depression. Ann N Y Acad Sci1999;877:614-637.
6.
Schildkraut JJ. The catecholamine hypothesis of affective disorders: a review of supporting evidence. Am J Psychiatry1965;122:509-522.
7.
Prange AJ Jr, Wilson IC, Lynn CW, Alltop LD, Stikeleather RS. L-tryptophan in mania. Contribution to a permissive hypothesis of affective disorders. Arch Gen Psychiatry1974;30:56-62.
8.
Duman RS, Heninger GR, Nestler EJ. A molecular and cellular theory of depression. Arch Gen Psychiatry1997;54:497-608.
9.
Beskow J, Gottfries CG, Roos BE, Winbald B.Determination on monoamine and monoamine metabolites in the human brain: post mortem studies in a group of suicides and in a control group. Acta Psychiatr Scand1976;53:7-20.
10.
Crow TJ, Cross AJ, Cooper SJ, Deakin JF, Ferrier IN, Johnson JA, et al.Neurotransmitter receptors and monoamine metabolites in the brains of patients with Alzheimer-type dementia and depression, and suicides. Neuropharmacology1984;23:1561-1569.
11.
Klimek V, Stockmeier C, Overholser J, Meltzer HY, Kalka S, Dilley G, et al.Reduced levels of norepinephrine transporters in the locus coeruleus in major depression. J Neurosci1997;17:8451-8458.
12.
Ordway GA, Smith KS, Haycock JW. Elevated tyrosine hydroxylase in the locus coeruleus of suicide victims. J Neurochem1999; 26:680-685.
13.
Ordway GA. Pathophysiology of the locus coeruleus in suicide. Ann N Y Acad Sci1997;29:233-252.
14.
Meyerson LR, Wennogle LP, Abel MS, Coupet J, Lippa AS, Rauh CE, et al.Human brain receptor alterations in suicide victims. Pharmacol Biochem Behav1982;17:159-163.
15.
Mann JJ, Stanley M, McBride PA, McEwen BS. Increase serotonin2 and beta-adrenergic receptor binding in the frontal cortices of suicide victims. Arch Gen Psychiatry1986;43:954-959.
16.
Beigon A, Israeli M.Regionally selective increases in beta-andrenergic receptor density in the brains of suicide victims. Brain Res1988;442:199-203.
17.
Arango V, Ernsberger P, Marzuk PM, Chen JS, Tierney H, Stanley M, et al.Autoradiographic demonstration of increased serotonin 5-HT2 and beta-adrenergic receptor binding site in the brain of suicide victims. Arch Gen Psychiatry1990;47:1038-1047.
18.
Trendelenburg AU, Limberger N, Rump LC. Alpha 2-andrenergic receptors of the alpha 2c subtype mediate inhibition of norepinephrine release in human kidney cortex. Mol Pharmacol1994;45:1168-1176.
19.
Esteban S, Llado J, Garcia-Sevilla JA. Alpha 2-autoreceptors and alpha 2-heteroreceptors modulating tyrosine and tryptophan hydroxylase activity in the rat brain in vivo: an investigation into the alpha 2-androceptor sub-types. Naunyn Schmiedebergs Arch Pharmacol1996;353:391-399.
20.
Meana JJ, Garcia-Sevilla JA. Increased alpha 2-adrenoceptor density in the frontal cortex of depressed suicide victims. J Neural Transm Gen Sect1987;70:377-381.
21.
Meana JJ, Barturen F, Garcia-Sevilla JA. Alpha 2-adrenoceptors in the brain of suicide victims: increased receptor density associated with major depression. Biol Psychiatry1992;31:471-490.
22.
Gonzales AM, Pascual J, Meana JJ, Barturen F, del Arco C, Pazos A, et al.Autoradiographic demonstration of increased alpha 2-andreoceptor agonist binding sites in the hippocampus and frontal cortex of depressed suicide victims. J Neurochem1994;63:256-265.
23.
Ordway GA, Widdowson PSM, Smith KS, Halaris A.Agonist binding to alpha 2-adrenocepters is elevated in the locus coeruleus from victims of suicide. J Neurochem1994;63: 617-624.
24.
De Paermentier F, Mauger JM, Lowther S, Crompton MR, Katona CL, Horton RW. Brain alpha-adrenoceptors in depressed suicides. Brain Res1997;757:60-68.
25.
Garcia-Sevilla JA, Escriba PV, Ozaita A, La Harpe R, Walzer C, Eytan A, et al.Up-regulation of immunolabeled alpha 2a-andrenoceptors, GI coupling proteins, and receptor kinases in the prefrontal cortex of depressed suicides. J Neurochem1999;72:282-291.
26.
Heninger GR, Charney DA, Sternber DE. Serotonin function in depression. Arch Gen Psychiatry1984;41:398-402.
27.
Cowen PJ, Charig EM. Neuroendocrine responses to trytophan in major depression. Arch Gen Psychiatry1987;44:958-966.
28.
Risch SC, Nemeroff CB. Neurochemical alterations of serotonergic neuronal systems in depression. J Clin Psychiatry1992;53:3-7.
29.
Arango V, Underwood MD, Gubbi AV, Mann JJ. Localized alterations in pre- and postsynaptic serotonin binding sites in the ventrolateral prefrontal cortex of suicide victims. Brain Res1995;688:121-133.
30.
Lowther S, de Paermentier F, Cheetham SC, Crompton MR, Katona CLE, Horton RW. 5-HT receptor binding sites in postmortem brain samples from depressed suicides and controls. J Affect Disord1997;42:199-207.
31.
Huang YY, Grailhe R, Arango V, Hen R, Mann JJ. Relationship of psychopathology to the human serotonin 1B genotype and receptor binding kinetics in postmortem brain tissue. Neuropsychopharmacology1999;21:238-246.
32.
Stanley M, Mann JJ. Increased serotonin-2 binding sites in frontal cortex of suicide victims. Lancet1983;1:214-216.
33.
Turecki G, Briere R, Dewar K, Antonelli T, Lesage AD, Seguin M, et al.Prediction of level of serotonin 2A receptor binding by serotonin receptor 2A genetic variation in postmortem brain samples from subjects who did or did not commit suicide. Am J Psychiatry1999;156:1456-1458.
34.
Hrdina PD, Demeter E, Vu TB, Sotonyi P, Palkovits M.5-HT uptake sites and 5-HT2 receptors in brain of antidepressant-free suicide victims/depressives: increase in 5-HT2 sites in cortex amygdala. Brain Res1993;614:37-44.
35.
Stockmeier CA, Shapiro LA, Dilley GE, Kolli TN, Friedman L, Rajkowska G.Increase in serotonin-1A autoreceptors in the midbrain of suicide victims with major depression—postmortem evidence for decreased serotonin activity. J Neurosci1998;18: 7394-7401.
36.
Roy A, Pickar D, Linnoila M, Dorna AR, Ninan P, Paul SM. Cerebrospinal fluid monoamine and monoamine metabolite concentrations in melancholia. Psychiatry Res1985;15:281-292.
37.
Mendels J, Frazer A, Fitzgerald RG, Ramsey TA, Stokes JW. Biogenic amine metabolites in the cerebrospinal fluid of depressed and manic patients. Science1972;175:1380-1382.
38.
Bowden C, Theodorou AE, Cheethan SC, Lowther S, Katona CLE, Crompton MR, et al.Dopamine D and D receptor binding sites in brain samples from depressed suicides and controls. Brain Res1997;752:227-233.
39.
England MA, Wakely J.A colour atlas of the brain and spinal cord. Aylesbury (UK): Mosby-Wolfe; 1991.
40.
Baumann B, Danos P, Krell D, Diekmann S, Leschinger A, Stauch R, et al.Reduced volume of limbic system-affiliated basal ganglia in mood disorders: preliminary data from a postmortem study. J Neuropsychiatry Clin Neursci1999;11:71-78.
41.
Pacheco MA, Stockmeier C, Meltzer HY, Overhosler JC, Dilley GE, Jope RS. Alterations in phosphoinositide signaling and G-protein levels in depressed suicide brain. Brain Res1996;723:37-45.
42.
Cowburn RF, Marcusson JO, Eriksson A, Wiehager B, O’Neill C.Adenylyl cyclase activity and G-protein subunit levels in postmortem frontal cortex of suicide victims. Brain Res1994;633:297-304.
43.
Lowther S, Crompton MR, Katona CL, Horton RW. GTP gamma S and forskolin-stimulated adenylyl cyclase activity in postmortem brain from depressed suicides and controls. Mol Psychiatry1996;1:470-477.
44.
Dowlatshahi D, MacQueen GM, Wang JF, Reiach JS, Young LT. G protein-coupled cyclic AMP signaling in postmortem brain of subjects with mood disorders: effects of diagnosis, suicide, and treatment at the time of death. J Neurochem1999;73:1121-1126.
45.
Reiach JS, Li PP, Warsh JJ, Kish SJ, Young LT. Reduced adenylyl cyclase immunolabeling and activity in postmortem temporal cortex of depressed suicide victims. J Affect Disord: in press.
46.
Wang JF, Li PP, Warsh JJ, Young LT. Signal transduction abnormalities in bipolar disorder. In: Young LT, Joffe RT, editors. Bipolar disorder: biological models and their clinical application. New York: Marcel Dekker; 1997. p. 41-80.
47.
Hrdina P, Faludi G, Li Q, Bendotti C, Tekes K, Sotonyi P, et al.Growth-associated protein (GAP-43), its mRNA, and protein kinase C (PKC) isoenzymes in brain regions of depressed suicides. Mol Psychiatry1998;3:411-418.
48.
McNamara RK, Hyde TM, Kleinman JE, Lenox RH. Expression of the myristoylated alanine-rich C kinase subtrate (MARCKS) and MARCKS-related protein (MRP) in the prefrontal cortex and hippocampus of suicide victims. J Clin Psychiatry1999; 60:21-26.
49.
Dowlatshahi D, MacQueen GM, Wang JF, Young LT. Increased temporal cortex CREB concentrations and antidepressant treatment in major depression. Lancet1998;352:1754.
50.
Bayer TA, Schramm M, Feldmann N, Knable MB, Falkai P.Antidepressant drug exposure is associated with mRNA levels of tyrosine receptor kinase B in major depressive disorder. Prog Neuropsychopharmacol Biol Psychiatry: in press.
51.
Ongur D, Drevets WC, Price JL. Glial reductin in the subgenual prefrontal cortex in mood disorders. Proc Natl Acad Sci U S A1998;95:13290-13295.
52.
Rajkowska G, Miguel-Hidalgo JJ, Wei J, Dilley G, Pittman SD, Meltzer HY, et al.Morphometric evidence for neuronal and glial prefrontal cell pathology in major depression. Biol Psychiatry1999;45:1085-1098.
53.
Honer WG, Falkai P, Chen C, Arango V, Mann JJ, Dwork AJ. Synaptic and plasticity-associated proteins in anterior frontal cortex in severe mental illness. Neuroscience1999;91:1247-1255.
54.
Kishimoto H, Yamada K, Iseki E, Kosaka K, Okoshi T.Brain imaging of affective disorders and schizophrenia. Psychiatry Clin Neurosci1998;52:S212-S214.
